Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'No Meaningful Change' In Pricing Environment, Teva Says

Executive Summary

Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."

You may also be interested in...

FTC Review Ongoing As Teva/Allergan Await Final Approval

Analysts had been expecting Teva's acquisition of Allergan's generics business to close at the end of June; Teva insists the acquisition is still going to plan.

Dr Reddy's Pumps Complex Generics Play with Teva deal

Dr. Reddy's Laboratories Ltd. is acquiring a basket of ANDAs from Teva Pharmaceutical Industries Ltd. as it increasingly leans towards developing and building a portfolio of complex and limited competition generics in the US and hopes to become "more relevant" there.

Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s

The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts